Engineers Gate Manager LP acquired a new stake in Edwards Lifesciences Corp (NYSE:EW) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,718 shares of the medical research company’s stock, valued at approximately $532,000.
Several other hedge funds and other institutional investors have also bought and sold shares of EW. OxFORD Asset Management LLP purchased a new position in Edwards Lifesciences in the second quarter worth approximately $708,000. Janus Henderson Group PLC lifted its stake in Edwards Lifesciences by 83.1% in the second quarter. Janus Henderson Group PLC now owns 50,178 shares of the medical research company’s stock worth $5,934,000 after acquiring an additional 22,768 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Edwards Lifesciences by 53.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock worth $1,418,000 after acquiring an additional 4,170 shares during the last quarter. Piedmont Investment Advisors LLC purchased a new position in Edwards Lifesciences in the second quarter worth approximately $435,000. Finally, Toronto Dominion Bank lifted its stake in Edwards Lifesciences by 24.0% in the second quarter. Toronto Dominion Bank now owns 71,106 shares of the medical research company’s stock worth $8,406,000 after acquiring an additional 13,747 shares during the last quarter. 81.31% of the stock is owned by institutional investors and hedge funds.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded up $0.48 during trading on Thursday, hitting $138.25. 914,974 shares of the stock were exchanged, compared to its average volume of 1,370,000. The firm has a market cap of $29,040.00, a PE ratio of 33.72, a price-to-earnings-growth ratio of 2.03 and a beta of 0.56. Edwards Lifesciences Corp has a fifty-two week low of $89.20 and a fifty-two week high of $138.82. The company has a quick ratio of 1.41, a current ratio of 1.80 and a debt-to-equity ratio of 0.15.
Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.03. The business had revenue of $888.50 million for the quarter, compared to analysts’ expectations of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The company’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 EPS. equities analysts expect that Edwards Lifesciences Corp will post 4.49 EPS for the current year.
Edwards Lifesciences declared that its Board of Directors has initiated a stock repurchase plan on Thursday, December 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.
A number of research analysts recently issued reports on EW shares. Cowen set a $135.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Sunday, December 10th. Evercore ISI started coverage on shares of Edwards Lifesciences in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 price target for the company. Barclays upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $135.00 in a research note on Thursday, January 4th. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Finally, Canaccord Genuity reissued a “buy” rating and set a $137.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, November 29th. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences presently has an average rating of “Buy” and an average price target of $141.15.
In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $114.08, for a total value of $604,624.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 5,633 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $136.29, for a total transaction of $767,721.57. Following the completion of the transaction, the vice president now directly owns 44,298 shares in the company, valued at $6,037,374.42. The disclosure for this sale can be found here. Insiders sold a total of 184,563 shares of company stock worth $22,358,569 over the last ninety days. Corporate insiders own 2.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/03/09/engineers-gate-manager-lp-acquires-shares-of-4718-edwards-lifesciences-corp-ew.html.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.